Glucotrack’s Innovative Blood Glucose Monitoring Concept Resonates with Patients with Diabetes, According to New Survey Presented at Association of Diabetes Care and Education Specialists (ADCES) 2024 Annual Conference
2024年8月15日 - 10:00PM
Glucotrack, Inc. (Nasdaq: GCTK) (“Glucotrack” or the “Company”), a
medical technology innovator focused on the design, development,
and commercialization of novel technologies for people with
diabetes, today announced new findings from a recent market
research study evaluating the acceptance of its new Continuous
Blood Glucose Monitor (CBGM) concept among people with
insulin-requiring diabetes. The poster was presented at the
Association of Diabetes Care and Education Specialists (ADCES) 2024
Annual Conference held Aug. 9-12, 2024, in New Orleans.
The study, conducted with a diverse group of
participants, revealed that over 50% of respondents are open to
adopting Glucotrack’s new CBGM concept – a small device placed
under the skin. This technology is designed to offer continuous,
accurate blood glucose monitoring for up to 3 years without the
calibration, comfort and wearability challenges associated with
traditional Continuous Glucose Monitor (CGM) approaches.
Key features that garnered the most interest
include the long-term sensor life (2-year sensor-life was tested
during the study), the absence of a wearable component, and the
provision of real-time blood glucose readings. These top three
appealing aspects were consistent across all segments of
respondents.
The study included 757 respondents with
intensive insulin therapy (49% type 1 diabetes and 51% type 2
diabetes), comprised of current CGM users (67%), non-users (25%)
and ex-users (8%). Respondents used various insulin delivery
methods: multiple daily injections (60%) and insulin pump (40%,
including 21% automated insulin delivery or AID and 19%
non-AID).
“This market research shows us that there is
clear need for innovation in continuous glucose monitoring and that
Glucotrack’s innovative approach has tremendous market potential as
it addresses unmet needs,” said Paul Goode, President & CEO at
Glucotrack. “Our goal has always been to develop innovative
solutions that improve the quality of life for people with
diabetes. The insights gained from this study will be invaluable as
we continue to refine our CBGM technology to better meet the needs
of our users.”
The new CBGM concept represents a significant
advancement in diabetes management, offering a more convenient and
less intrusive way for individuals to monitor their blood glucose
levels. Glucotrack remains committed to leveraging cutting-edge
technology to empower people with diabetes to live healthier, more
independent lives.
Glucotrack, Inc. has recently made significant
strides in its clinical progress. The company successfully
completed a 60-day long-term preclinical study of its implantable
CGM, demonstrating the feasibility of glucose monitoring in the
epidural space. Additionally, a 90-day preclinical study confirmed
the sustained accuracy of its CBGM, with a mean absolute relative
difference of 4.7%, which is considered highly accurate for a
continuous glucose monitor. These advancements pave the way for
upcoming human clinical trials that the company plans to initiate
later this year, marking a crucial step towards providing a more
convenient and discreet glucose monitoring solution for people with
diabetes.
For more information about Glucotrack’s CBGM,
visit glucotrack.com.
# # #
About Glucotrack, Inc.
Glucotrack, Inc. (NASDAQ: GCTK) is focused on
the design, development, and commercialization of novel
technologies for people with diabetes. The Company is currently
developing a long-term implantable continuous blood glucose
monitoring system for people living with diabetes.
Glucotrack’s CBGM is a long-term, implantable
system that continually measures blood glucose levels with a sensor
longevity of 2+ years, no on-body wearable component and with
minimal calibration. For more information, please
visit http://www.glucotrack.com.
Forward-Looking Statements
This news release contains forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995. Statements contained in this news release that
are not statements of historical fact may be deemed to be
forward-looking statements. Without limiting the generality of the
foregoing, words such as “believe”, “expect”, “plan” and “will” are
intended to identify forward-looking statements. Such
forward-looking statements are based on the beliefs of management,
as well as assumptions made by, and information currently available
to, management. These statements relate only to events as of the
date on which the statements are made, and Glucotrack undertakes no
obligation to publicly update any forward-looking statements,
whether as a result of new information, future events or otherwise,
except as required by law. All of the forward-looking statements
made in this press release are qualified by these cautionary
statements, and there can be no assurance that the actual results
anticipated by Glucotrack will be realized or, even if
substantially realized, that they will have the expected
consequences to or effects on us or our business or operations.
Readers are cautioned that certain important factors may affect
Glucotrack’s actual results and could cause such results to differ
materially from any forward-looking statements that may be made in
this news release. Factors that may affect Glucotrack’s results
include, but are not limited to, the ability of Glucotrack to raise
additional capital to finance its operations (whether through
public or private equity offerings, debt financings, strategic
collaborations or otherwise); risks relating to the receipt (and
timing) of regulatory approvals (including U.S. Food and Drug
Administration approval); risks relating to enrollment of patients
in, and the conduct of, clinical trials; risks relating to
Glucotrack’s future distribution agreements; risks relating to its
ability to hire and retain qualified personnel, including sales and
distribution personnel; and the additional risk factors described
in Glucotrack’s filings with the U.S. Securities and Exchange
Commission (the “SEC”), including its Annual Report on Form 10-K
for the year ended December 31, 2023 as filed with the SEC on March
28, 2024.
Contacts:
Investor Relations:investors@glucotrack.com
Media:GlucotrackPR@icrinc.com
GlucoTrack (NASDAQ:GCTK)
過去 株価チャート
から 8 2024 まで 9 2024
GlucoTrack (NASDAQ:GCTK)
過去 株価チャート
から 9 2023 まで 9 2024